Huron sells healthcare revenue cycle and performance improvement consulting, plus enterprise technology implementation and education services, primarily to hospitals, health systems and universities. Its moat rests on embedded client relationships and domain-specific expertise, which keep engagements sticky and demand resilient when hospital finances tighten. Revenue growth of 15.7% is running well ahead of what most consulting peers are delivering, and the company is still reporting a 26.9% return on equity on a 2.8 billion dollar market cap. The stock trades at 15.5 times forward earnings against a trailing multiple of 26.6, so the market is pricing in a meaningful step-up in profitability, and that gap is the first thing to test. Operating margin of 11.7% is the number to scrutinize, since the thesis depends on whether recent growth can translate into margin expansion rather than being bought with labor-heavy hiring.
Plain-English pros, cons, and what to watch. Pro feature.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
Trades are only made public after a delay. We show the delay so you know how old the news is.
Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.
| Date | Type | New | Previous | Price |
|---|---|---|---|---|
| 20 Oct 2026, 15:04 CEST | Rating | Overvalued | first publication | $175 |
| 20 Oct 2026, 15:04 CEST | Fair value | $146 | $210 | $175 |
| 16 Oct 2026, 00:00 CEST | Fair value | $210 | $216 | $175 |
| 11 Oct 2026, 00:00 CEST | ACCE price target | $182 | first publication | $167 |
| 11 Oct 2026, 00:00 CEST | Fair value | $216 | $131 | $167 |
| 7 Oct 2026, 00:00 CEST | Fair value | $131 | $130 | $160 |
| 4 Oct 2026, 00:00 CEST | Fair value | $130 | $132 | $162 |
| 27 Sept 2026, 00:00 CEST | Fair value | $132 | $134 | $158 |
| 25 Sept 2026, 00:00 CEST | Fair value | $134 | $131 | $160 |
| 13 Sept 2026, 00:00 CEST | Fair value | $131 | $129 | $150 |
Answered from Huron Consulting Group Inc. Common Stock fundamentals + recent valuations. Every number shows its source and date.
| Company | Price | Fair value | vs fair value | P/E | ROE | Quality | Score |
|---|---|---|---|---|---|---|---|
| HURN Huron Consulting Group Inc. Common Stock | $195.69 | $146 | 34% above | 28.0x | 26.9% | 69 | 77 |
| FCN FTI Consulting Inc. Common Stock | $157.24 | $166 | 5% below | 18.9x | 15.6% | 64 | 50 |
| ICFI ICF International Inc. Common Stock | $94.40 | $106 | 11% below | 18.8x | 8.6% | 56 | 63 |
| IPS.PA Ipsos SA | €35.30 | €60 | 42% below | 8.8x | 11.9% | 67 | 62 |
| DKSH.SW DKSH Holding AG | CHF 77.10 | CHF 53 | 45% above | 23.7x | 12.6% | 40 | 62 |
| ALQ.AX ALS Limited | A$19.71 | A$13 | 46% above | 32.3x | 21.4% | 68 | 58 |
| CRAI CRA International Inc. Common Stock | $200.14 | $140 | 43% above | 26.8x | 26.0% | 74 | 70 |
Where HURN ranks against its sector peers on each metric.